Ho-Ping Yu1, Hsu-Lung Jen2, Wei-Hsian Yin3, Jeng Wei1. 1. Heart Center, Cheng Hsin General Hospital. 2. Heart Center, Cheng Hsin General Hospital; ; Institute of Clinical Medicine. 3. Heart Center, Cheng Hsin General Hospital; ; Faculty of Medicine; ; Cardiovascular Research Centre, National Yang-Ming University, School of Medicine, Taipei, Taiwan.
Abstract
BACKGROUND: Circulating adiponectin concentration increases in patients with chronic heart failure (HF). We sought to explore the prognostic value of temporal changes in adiponectin concentration following treatment for chronic HF. METHODS: Serum adiponectin levels were measured at baseline and after a 3-month anti-failure treatment in 124 patients with symptomatic chronic systolic HF. Major adverse cardiac events (MACE) including death, heart transplantation, or hospitalization with worsening HF during a median follow-up period of 752 days were determined. RESULTS: Univariate and multivariate analysis showed that high levels of adiponectin after a 3-month treatment were associated with a 3.8-fold increased risk of MACE (p = 0.03), independent of amino-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Moreover, the combining of circulating levels of adiponectin with NT-proBNP provided independent and additional prognostic value in identifying high risk patients with MACE during follow-up. CONCLUSIONS: Changes in adiponectin and NT-proBNP over time provide prognostic information. When adiponectin is used in conjunction with NT-proBNP in chronic HF, the prognostic value may be better than if each biomarker is used separately.
BACKGROUND: Circulating adiponectin concentration increases in patients with chronic heart failure (HF). We sought to explore the prognostic value of temporal changes in adiponectin concentration following treatment for chronic HF. METHODS: Serum adiponectin levels were measured at baseline and after a 3-month anti-failure treatment in 124 patients with symptomatic chronic systolic HF. Major adverse cardiac events (MACE) including death, heart transplantation, or hospitalization with worsening HF during a median follow-up period of 752 days were determined. RESULTS: Univariate and multivariate analysis showed that high levels of adiponectin after a 3-month treatment were associated with a 3.8-fold increased risk of MACE (p = 0.03), independent of amino-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Moreover, the combining of circulating levels of adiponectin with NT-proBNP provided independent and additional prognostic value in identifying high risk patients with MACE during follow-up. CONCLUSIONS: Changes in adiponectin and NT-proBNP over time provide prognostic information. When adiponectin is used in conjunction with NT-proBNP in chronic HF, the prognostic value may be better than if each biomarker is used separately.
Authors: Yong Qi; Nobuhiko Takahashi; Stanley M Hileman; Hiralben R Patel; Anders H Berg; Utpal B Pajvani; Philipp E Scherer; Rexford S Ahima Journal: Nat Med Date: 2004-04-11 Impact factor: 53.440
Authors: Ugur Nadir Karakulak; Sercan Okutucu; Utku Lokman; Ovunc Bilgin; Engin Tutkun; Omer Hinc Yilmaz; Ali Oto Journal: Acta Cardiol Sin Date: 2019-01 Impact factor: 2.672